Pub Date : 2026-01-09DOI: 10.1016/j.gastrohep.2026.502652
Domingo Balderramo, Joaquín Montero, Juan Lasa, Ramiro Cruz González Sueyro, Pablo Andrés Olivera, Alicia Sambuelli, Abel Novillo, Juan Andrés De Paula
Objective: There is little information available at the national level on inflammatory bowel disease (IBD) in Argentina. The objective was to describe the methodology of the Argentinian Crohn's Disease and Ulcerative Colitis Registry (RADECCU).
Patient and methods: RADECCU was developed in 2023 with the aim of facilitating the collection of relevant information from patients with IBD in Argentina. After the registry's website platform was developed (01/2023), a nationwide promotion campaign was carried out to incorporate centers into RADECCU.
Results: From 02/2023 to 6/2025, 69 centers (41 private, 28 public) were incorporated, including 142 professionals, and 4081 patients (2275 women and 1806 men) were enrolled in the registry.
Conclusion: RADECCU is the first national IBD registry in Argentina. This registry will provide information on the status of IBD in Argentina and contribute to Latin American data with the potential to generate real-world evidence on different aspects of interest.
{"title":"The Argentinian Crohn's Disease and Ulcerative Colitis Registry (RADECCU): Methodological aspects and objectives.","authors":"Domingo Balderramo, Joaquín Montero, Juan Lasa, Ramiro Cruz González Sueyro, Pablo Andrés Olivera, Alicia Sambuelli, Abel Novillo, Juan Andrés De Paula","doi":"10.1016/j.gastrohep.2026.502652","DOIUrl":"10.1016/j.gastrohep.2026.502652","url":null,"abstract":"<p><strong>Objective: </strong>There is little information available at the national level on inflammatory bowel disease (IBD) in Argentina. The objective was to describe the methodology of the Argentinian Crohn's Disease and Ulcerative Colitis Registry (RADECCU).</p><p><strong>Patient and methods: </strong>RADECCU was developed in 2023 with the aim of facilitating the collection of relevant information from patients with IBD in Argentina. After the registry's website platform was developed (01/2023), a nationwide promotion campaign was carried out to incorporate centers into RADECCU.</p><p><strong>Results: </strong>From 02/2023 to 6/2025, 69 centers (41 private, 28 public) were incorporated, including 142 professionals, and 4081 patients (2275 women and 1806 men) were enrolled in the registry.</p><p><strong>Conclusion: </strong>RADECCU is the first national IBD registry in Argentina. This registry will provide information on the status of IBD in Argentina and contribute to Latin American data with the potential to generate real-world evidence on different aspects of interest.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502652"},"PeriodicalIF":1.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1016/j.gastrohep.2025.502651
Ana Fernández Lamelas, Ariadna Gil Díaz, Raquel Latorre Martínez, Daniel Alcalde Rodríguez, Alicia Bejerano Domínguez, Esteban Fuentes-Valenzuela
{"title":"Scrotal extension of an acute pancreatic collection: A diagnostic and therapeutic challenge.","authors":"Ana Fernández Lamelas, Ariadna Gil Díaz, Raquel Latorre Martínez, Daniel Alcalde Rodríguez, Alicia Bejerano Domínguez, Esteban Fuentes-Valenzuela","doi":"10.1016/j.gastrohep.2025.502651","DOIUrl":"10.1016/j.gastrohep.2025.502651","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502651"},"PeriodicalIF":1.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145899554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502496
Ignacio Antonio Gemio del Rey , Roberto de la Plaza Llamas , Daniel Alejandro Díaz Candelas , Ludovica Gorini , Rodrigo Arellano González
{"title":"Uso del PET en la determinación preoperatoria de la malignidad de los schwannomas gástricos. Revisión sistemática de la literatura y aportación de un caso","authors":"Ignacio Antonio Gemio del Rey , Roberto de la Plaza Llamas , Daniel Alejandro Díaz Candelas , Ludovica Gorini , Rodrigo Arellano González","doi":"10.1016/j.gastrohep.2025.502496","DOIUrl":"10.1016/j.gastrohep.2025.502496","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502496"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502538
Marc Lleixà-Rioboo , Andrés Arango , Alexandre Rey , Ignasi Elizalde , Eva C. Vaquero , Míriam Cuatrecasas , Ariadna Sánchez , María Daca-Álvarez
{"title":"Appendiceal angiodysplasia: An unexpected cause of gastrointestinal bleeding","authors":"Marc Lleixà-Rioboo , Andrés Arango , Alexandre Rey , Ignasi Elizalde , Eva C. Vaquero , Míriam Cuatrecasas , Ariadna Sánchez , María Daca-Álvarez","doi":"10.1016/j.gastrohep.2025.502538","DOIUrl":"10.1016/j.gastrohep.2025.502538","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502538"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502577
Joan B. Gornals , Julia Escuer-Turu , Maria Puigcerver-Mas
{"title":"Endoscopic journey to the center of the pancreas: ‘Ring Drainage’ (gastro-pancreato-duodenal)","authors":"Joan B. Gornals , Julia Escuer-Turu , Maria Puigcerver-Mas","doi":"10.1016/j.gastrohep.2025.502577","DOIUrl":"10.1016/j.gastrohep.2025.502577","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502577"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502493
Aingeru Sarriugarte Lasarte , Hector Marín Ortega , Miren San Martin Murillo , Silvia Perez Fernandez , Gerardo Moro Portela , Beatriz Villota Tamayo , Javier Uriarte Gonzalez , Jasone Larrea Oleaga , Raul Saa Álvarez
Objectives
Pancreatic surgery is burdened with high morbidity and mortality. There are quality indicators of the surgical process known as textbook outcomes (TO) that have been validated in areas such as esophagogastric surgery or liver surgery, and are beginning to be used in pancreatic surgery. This indicator assesses the absence of: 1) Mortality, 2) Pancreatic fistula, 3) Hemorrhage, 4) Biliary fistula, 5) Clavien-Dindo > II and 6) Readmission; TO is considered if all criteria are got. The aim of this study is to assess the impact of the achievement of TO on the prognosis of pancreatic adenocarcinoma.
Patients and methods
Retrospective comparative study between two periods; before and after the creation of a pancreatic surgery unit. The results have been evaluated using Textbook Outcomes and the impact on survival of the achievement of these criteria was analyzed.
Results
A total of 185 patients with pancreatic adenocarcinoma were analyzed, divided into two 5-year periods before and after the creation of the pancreatic surgery unit. There were no significant differences in clinical-pathological variables. Since the creation of the unit, TO achievement increased from 47 to 80.7% (P<.05). The OS of patients at 1, 2, and 3 years in the groups with and without TO criteria fulfillment was 86.9, 55.7, 41 and 62.7, 40.3 and 31.3% respectively, with a statistically significant difference as shown in Image 1 (P=.013). Multivariate analysis of OS showed that compliance with all TOs significantly affects mortality (HR: 0.5 [0.31-0.81]; P=.004).
Conclusion
The results support the hypothesis that the achievement of the TO surgical quality criteria has a positive impact on the oncological prognosis of curative surgery for pancreatic cancer. Centralization of pancreatic cancer surgery could help to meet the surgical quality criteria largely and thus improve the prognosis of patients.
{"title":"Valoración del indicador de calidad de la cirugía «textbook outcomes» como factor de buen pronóstico del adenocarcinoma de páncreas","authors":"Aingeru Sarriugarte Lasarte , Hector Marín Ortega , Miren San Martin Murillo , Silvia Perez Fernandez , Gerardo Moro Portela , Beatriz Villota Tamayo , Javier Uriarte Gonzalez , Jasone Larrea Oleaga , Raul Saa Álvarez","doi":"10.1016/j.gastrohep.2025.502493","DOIUrl":"10.1016/j.gastrohep.2025.502493","url":null,"abstract":"<div><h3>Objectives</h3><div>Pancreatic surgery is burdened with high morbidity and mortality. There are quality indicators of the surgical process known as textbook outcomes (TO) that have been validated in areas such as esophagogastric surgery or liver surgery, and are beginning to be used in pancreatic surgery. This indicator assesses the absence of: 1) Mortality, 2) Pancreatic fistula, 3) Hemorrhage, 4) Biliary fistula, 5) Clavien-Dindo<!--> <!-->><!--> <!-->II and 6) Readmission; TO is considered if all criteria are got. The aim of this study is to assess the impact of the achievement of TO on the prognosis of pancreatic adenocarcinoma.</div></div><div><h3>Patients and methods</h3><div>Retrospective comparative study between two periods; before and after the creation of a pancreatic surgery unit. The results have been evaluated using Textbook Outcomes and the impact on survival of the achievement of these criteria was analyzed.</div></div><div><h3>Results</h3><div>A total of 185 patients with pancreatic adenocarcinoma were analyzed, divided into two 5-year periods before and after the creation of the pancreatic surgery unit. There were no significant differences in clinical-pathological variables. Since the creation of the unit, TO achievement increased from 47 to 80.7% (<em>P</em><.05). The OS of patients at 1, 2, and 3 years in the groups with and without TO criteria fulfillment was 86.9, 55.7, 41 and 62.7, 40.3 and 31.3% respectively, with a statistically significant difference as shown in Image 1 (<em>P</em>=.013). Multivariate analysis of OS showed that compliance with all TOs significantly affects mortality (HR: 0.5 [0.31-0.81]; <em>P</em>=.004).</div></div><div><h3>Conclusion</h3><div>The results support the hypothesis that the achievement of the TO surgical quality criteria has a positive impact on the oncological prognosis of curative surgery for pancreatic cancer. Centralization of pancreatic cancer surgery could help to meet the surgical quality criteria largely and thus improve the prognosis of patients.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502493"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502528
Francesc Casellas , Ana Gutiérrez-Casbas , Cristina Rodríguez , Javier P. Gisbert , Sabino Riestra , Claudia Herrera de Guise , Isabel Vera-Mendoza , Pilar Martínez-Montiel , Sónia Bernardo , Isabel Medeiros , Jesús Aparicio , Ignacio Tagarro , Teresa Letosa-Abián , Carmen Montoto , Fernando Muñoz
Objective
Real-world evidence (RWE) on vedolizumab (VDZ), an anti-lymphocyte trafficking treatment that selectively targets the α4β7/MAdCAM-1 interaction on the gut, is mostly limited to patients who are repeatedly refractory to anti-tumor necrosis factor-alpha (anti-TNF-α), and other treatments. The EVOLVE-IBERIA study assessed VDZ or anti-TNF-α as first- or second-line biologic treatment, in patients with Crohn's disease or ulcerative colitis (UC); here, we present the outcomes in patients with UC.
Patients and methods
Medical records were retrospectively reviewed from 25 hospitals in Spain and Portugal. Eligible patients with UC were aged ≥18 years and had received treatment with first- or second-line VDZ or anti-TNF-α. Objectives were to evaluate clinical effectiveness, safety, and treatment patterns of VDZ and anti-TNF-α, and to characterize healthcare resource utilization. Baseline covariates were balanced in both cohorts by means of propensity scores, using the inverse probability of treatment weighting (PS-IPTW) method.
Results
A total of 199 patients with UC were included (median follow-up: 24.0 months). At Week 52, clinical response rates were 75.6% and 73.2% (p = 0.72) and clinical remission rates were 56.6% and 62.0% (p = 0.49), in the VDZ cohort and anti-TNF-α cohort, respectively. Treatment-related adverse event rates per 100 patient-years were 0.23 in the VDZ cohort and 1.1 in the anti-TNF-α cohort (p = 0.037).
Conclusion
The similar long-term effectiveness and lower incidence of adverse events of VDZ compared with anti-TNF-α in the real-world setting, confirm the favorable benefit:risk ratio of VDZ as first- or second-line biologic treatment for UC.
{"title":"EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitis","authors":"Francesc Casellas , Ana Gutiérrez-Casbas , Cristina Rodríguez , Javier P. Gisbert , Sabino Riestra , Claudia Herrera de Guise , Isabel Vera-Mendoza , Pilar Martínez-Montiel , Sónia Bernardo , Isabel Medeiros , Jesús Aparicio , Ignacio Tagarro , Teresa Letosa-Abián , Carmen Montoto , Fernando Muñoz","doi":"10.1016/j.gastrohep.2025.502528","DOIUrl":"10.1016/j.gastrohep.2025.502528","url":null,"abstract":"<div><h3>Objective</h3><div>Real-world evidence (RWE) on vedolizumab (VDZ), an anti-lymphocyte trafficking treatment that selectively targets the α4β7/MAdCAM-1 interaction on the gut, is mostly limited to patients who are repeatedly refractory to anti-tumor necrosis factor-alpha (anti-TNF-α), and other treatments. The EVOLVE-IBERIA study assessed VDZ or anti-TNF-α as first- or second-line biologic treatment, in patients with Crohn's disease or ulcerative colitis (UC); here, we present the outcomes in patients with UC.</div></div><div><h3>Patients and methods</h3><div>Medical records were retrospectively reviewed from 25 hospitals in Spain and Portugal. Eligible patients with UC were aged ≥18 years and had received treatment with first- or second-line VDZ or anti-TNF-α. Objectives were to evaluate clinical effectiveness, safety, and treatment patterns of VDZ and anti-TNF-α, and to characterize healthcare resource utilization. Baseline covariates were balanced in both cohorts by means of propensity scores, using the inverse probability of treatment weighting (PS-IPTW) method.</div></div><div><h3>Results</h3><div>A total of 199 patients with UC were included (median follow-up: 24.0 months). At Week 52, clinical response rates were 75.6% and 73.2% (<em>p</em> <!-->=<!--> <!-->0.72) and clinical remission rates were 56.6% and 62.0% (<em>p</em> <!-->=<!--> <!-->0.49), in the VDZ cohort and anti-TNF-α cohort, respectively. Treatment-related adverse event rates per 100 patient-years were 0.23 in the VDZ cohort and 1.1 in the anti-TNF-α cohort (<em>p</em> <!-->=<!--> <!-->0.037).</div></div><div><h3>Conclusion</h3><div>The similar long-term effectiveness and lower incidence of adverse events of VDZ compared with anti-TNF-α in the real-world setting, confirm the favorable benefit:risk ratio of VDZ as first- or second-line biologic treatment for UC.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502528"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502560
Mónica Egea Sancho , José Ignacio Ramírez-Manent , Pedro Juan Tárraga López , Irene Coll Campayo , María Teófila Vicente-Herrero , Ángel Arturo López-González
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, particularly among individuals with obesity. While metabolic and behavioral risk factors have been well described, the role of psychosocial determinants, such as weight stigma, remains underexplored.
Objectives
To assess the association between sociodemographic variables, healthy lifestyle behaviors, and internalized weight stigma with MASLD risk in a large cohort of obese workers across Spain.
Patients and methods
This cross-sectional study analyzed data from 26,816 obese employees who underwent occupational health screenings between January 2021 and December 2024. MASLD risk was assessed using three validated indices: the Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), and Lipid Accumulation Product (LAP). Sociodemographic characteristics, adherence to the Mediterranean diet, physical activity, smoking status, and weight stigma (assessed by the Weight Bias Internalization Scale) were evaluated. Multivariable logistic regression models were used to estimate associations.
Results
Weight stigma was significantly associated with higher risk of MASLD across all three indices, independent of age, sex, social class, and health behaviors. Participants with internalized weight stigma were 1.6–2.3 times more likely to present with high-risk scores. Sociodemographic disparities and unhealthy lifestyle factors also contributed to elevated MASLD risk.
Conclusions
Beyond metabolic and behavioral determinants, internalized weight stigma emerges as a strong independent factor associated with MASLD risk. These findings underscore the importance of incorporating psychosocial components into liver disease prevention strategies in occupational settings.
{"title":"Associations of sociodemographic factors, healthy habits, and weight stigma with non-alcoholic fatty liver disease risk in obese workers: Findings from a large occupational cohort","authors":"Mónica Egea Sancho , José Ignacio Ramírez-Manent , Pedro Juan Tárraga López , Irene Coll Campayo , María Teófila Vicente-Herrero , Ángel Arturo López-González","doi":"10.1016/j.gastrohep.2025.502560","DOIUrl":"10.1016/j.gastrohep.2025.502560","url":null,"abstract":"<div><h3>Background</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, particularly among individuals with obesity. While metabolic and behavioral risk factors have been well described, the role of psychosocial determinants, such as weight stigma, remains underexplored.</div></div><div><h3>Objectives</h3><div>To assess the association between sociodemographic variables, healthy lifestyle behaviors, and internalized weight stigma with MASLD risk in a large cohort of obese workers across Spain.</div></div><div><h3>Patients and methods</h3><div>This cross-sectional study analyzed data from 26,816 obese employees who underwent occupational health screenings between January 2021 and December 2024. MASLD risk was assessed using three validated indices: the Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), and Lipid Accumulation Product (LAP). Sociodemographic characteristics, adherence to the Mediterranean diet, physical activity, smoking status, and weight stigma (assessed by the Weight Bias Internalization Scale) were evaluated. Multivariable logistic regression models were used to estimate associations.</div></div><div><h3>Results</h3><div>Weight stigma was significantly associated with higher risk of MASLD across all three indices, independent of age, sex, social class, and health behaviors. Participants with internalized weight stigma were 1.6–2.3<!--> <!-->times more likely to present with high-risk scores. Sociodemographic disparities and unhealthy lifestyle factors also contributed to elevated MASLD risk.</div></div><div><h3>Conclusions</h3><div>Beyond metabolic and behavioral determinants, internalized weight stigma emerges as a strong independent factor associated with MASLD risk. These findings underscore the importance of incorporating psychosocial components into liver disease prevention strategies in occupational settings.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502560"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号